First renin inhibitor, aliskiren, for the treatment of hypertension

Pharmacy World and Science

Volumn 30, Issue 6, 2008, Pages 741-749

  Triller, Darren M ^a   Evang, Samuel D ^b   Tadrous, Mina ^b   Yoo, Bong Kyu ^c  

^a IPRO Inc   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c Yeungnam University   (South Korea)

Author keywords

Adverse events; Aliskiren; Blood pressure; Efficacy; Hypertension; Renin inhibitor

Indexed keywords

ALISKIREN; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; IRBESARTAN; PLACEBO; RENIN; RENIN INHIBITOR; VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE COUNT; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; MEDLINE; MONOTHERAPY; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL;

AMIDES; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CLINICAL TRIALS, PHASE III AS TOPIC; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FUMARATES; HUMANS; HYPERTENSION; RENIN;

EID: 56549103332     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-008-9252-1     Document Type: Review

References (31)

1. Approval Letter. http://www.fda.gov/cder/foi/nda/2007/021985s000_APPROV. pdf Accessed on 23 June 2008.
2. Pharmacology Review Part 2. http://www.fda.gov/cder/foi/nda/2007/ 021985s000_PharmR_P2.pdf Accessed on 23 June 2008.
3. Pharmacology Review Part 3. http://www.fda.gov/cder/foi/nda/2007/ 021985s000_PharmR_P3.pdf Accessed on 23 June 2008.
4. JM Wood J Maibaum J Rahuel MG Grutter NC Cohen V Rasetti 2003 Structure-based design of aliskiren, a novel orally effective renin inhibitor Biochem Biophys Res Commun 308 698 705 10.1016/S0006-291X(03)01451-7
5. A Stanton C Jensen J Nussberger E O'Brien 2003 Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren Hypertension 42 1137 43 10.1161/01.HYP.0000101688.17370.87
6. M Azizi J Ménard A Bissery TT Guyenne A Bura-Rivière S Vaidyanathan 2004 Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption J Am Soc Nephrol 15 3126 33 10.1097/01.ASN.0000146686.35541.29
7. JE Sealey JH Laragh 2007 Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness Am J Hypertens 20 587 97 10.1016/j.amjhyper.2007.04.001
8. J Nussberger G Wuerzner C Jensen HR Brunner 2002 Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril Hypertension 39 E1 8 10.1161/hy0102.102293
9. J Kalus 2006 Aliskiren: a novel oral renin inhibitor for the treatment of hypertension Formulary 41 631 8
10. BH Oh J Mitchell JR Herron J Chung M Khan DL Keefe 2007 Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension J Am Coll Cardiol 49 1157 63 10.1016/j.jacc.2006.11.032
11. A Villamil SG Chrysant D Calhoun B Schober H Hsu L Matrisciano-Dimichino 2007 Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide J Hypertens 25 217 26 10.1097/HJH.0b013e3280103a6b
12. BH Oh 2007 Aliskiren, the first in a new class of direct renin inhibitors for hypertension: present and future perspectives Expert Opin Pharmacother 8 2839 49 10.1517/14656566.8.16.2839
13. R Sepehrdad WH Frishman CT Stier Jr DA Sica 2007 Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren Cardiol Rev 15 242 56 10.1097/CRD.0b013e318093e43a
14. BW Van Tassell MA Munger 2007 Aliskiren for renin inhibition: a new class of antihypertensives Ann Pharmacother 41 456 64 10.1345/aph.1H549
15. JE Frampton MP Curran 2007 Aliskiren: a review of its use in the management of hypertension Drugs 67 1767 92 10.2165/00003495-200767120-00008
16. AH Gradman D Traub 2007 The efficacy of aliskiren, a direct renin inhibitor, in the treatment of hypertension Rev Cardiovasc Med 8 Suppl 2 S22 30
17. E O'Brien 2006 Aliskiren: a renin inhibitor offering a new approach for the treatment of hypertension Expert Opin Investig Drugs 15 1269 77 10.1517/13543784.15.10.1269
18. T Kushiro H Itakura Y Abo H Gotou S Terao DL Keefe 2006 Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension Hypertens Res 29 997 1005 10.1291/hypres.29.997
19. AH Gradman RE Schmieder RL Lins J Nussberger Y Chiang MP Bedigian 2005 Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients Circulation 111 1012 8 10.1161/01.CIR.0000156466.02908.ED
20. S Oparil SA Yarows S Patel H Fang J Zhang A Satlin 2007 Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial Lancet 370 221 9 10.1016/S0140-6736(07)61124-6
21. JL Pool RE Schmieder M Azizi JC Aldigier A Januszewicz W Zidek 2007 Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan Am J Hypertens 20 11 20 10.1016/j.amjhyper.2006.06.003
22. Label Information of Tekturna. http://www.fda.gov/cder/foi/nda/2007/ 021985s000_PRNTLBL.pdf Accessed on 23 June 2008.
23. Medical Review Part 1. http://www.fda.gov/cder/foi/nda/2007/ 021985s000_MedR_P1.pdf Accessed on 23 June 2008.
24. Medical Review Part 2. http://www.fda.gov/cder/foi/nda/2007/ 021985s000_MedR_P2.pdf Accessed on 23 June 2008.
25. Medical Review Part 3. http://www.fda.gov/cder/foi/nda/2007/ 021985s000_MedR_P3.pdf Accessed on 23 June 2008.
26. Pharmacology Review Part 4. http://www.fda.gov/cder/foi/nda/2007/ 021985s000_PharmR_P4.pdf Accessed on 23 June 2008.
27. World Health Organization. Chapter 4: Quantifying selected major risks to health. In: The World Health Report 2002 (reducing risks, promoting healthy life). Geneva, Switzerland, 2002. p. 57.
28. AV Chobanian GL Bakris HR Black WC Cushman LA Green JL Izzo Jr 2003 Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure Hypertension 42 1206 52 10.1161/01.HYP.0000107251.49515.c2
29. AD Efstratopoulos SM Voyaki AA Baltas FA Vratsistas DE Kirlas JT Kontoyannis 2006 Prevalence, awareness, treatment and control of hypertension in Hellas, Greece: the hypertension study in general practice in Hellas (HYPERTENSHELL) national study Am J Hypertens 19 53 60 10.1016/j.amjhyper.2005. 07.011
30. I Hajjar TA Kotchen 2003 Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000 JAMA 290 199 206 10.1001/jama.290.2.199
31. J Nussberger AH Gradman RE Schmieder RL Lins Y Chiang MF Prescott 2007 Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension Int J Clin Pract 61 1461 8 10.1111/j.1742-1241.2007.01473.x